Analyzing Collegium Pharmaceutical (COLL) and Its Rivals

Collegium Pharmaceutical (NASDAQ: COLL) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Collegium Pharmaceutical to related companies based on the strength of its dividends, earnings, valuation, profitability, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Collegium Pharmaceutical and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Collegium Pharmaceutical $7.44 million -$97.95 million -3.10
Collegium Pharmaceutical Competitors $8.17 billion $2.69 billion -0.31

Collegium Pharmaceutical’s competitors have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Collegium Pharmaceutical and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 0 5 0 3.00
Collegium Pharmaceutical Competitors 816 3669 6686 180 2.55

Collegium Pharmaceutical currently has a consensus target price of $20.00, indicating a potential upside of 76.06%. As a group, “Pharmaceuticals” companies have a potential upside of 22.28%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than its competitors.

Volatility and Risk

Collegium Pharmaceutical has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s competitors have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.

Insider & Institutional Ownership

83.0% of Collegium Pharmaceutical shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.8% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Collegium Pharmaceutical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical -1,319.39% -93.73% -74.81%
Collegium Pharmaceutical Competitors -2,882.43% -67.86% -8.82%

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply